Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mds465PMID 32018415
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.

  2012cited by this paper
• Therapeutic strategy in unresectable metastatic colorectal cancer

  2012cited by this paper
• Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan

  2011cited by this paper
• External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds.

  2011cited by this paper
• Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

  2011cited by this paper
• Increased epidermal growth factor receptor expression at the invasive margin is a negative prognostic factor in colorectal cancer

  2011cited by this paper
• Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC).

  2011cited by this paper
• Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.

  2011cited by this paper
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

  2010cited by this paper
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

  2010cited by this paper
• Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

  2010cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010cited by this paper
• Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer.

  2010cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

  2009cited by this paper
• Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.

  2008cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Cetuximab for the treatment of colorectal cancer.

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Epidermal growth factor receptor analyses in colorectal cancer: a comparison of methods.

  2006cited by this paper
• Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  2006cited by this paper
• Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines

  2005cited by this paper
• Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

  2005cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cells

  2004cited by this paper
• Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.

  2002cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Physical Interaction between Epidermal Growth Factor Receptor and DNA-dependent Protein Kinase in Mammalian Cells*

  1998cited by this paper
• A note on quantifying follow-up in studies of failure time.

  1996cited by this paper

• Molecular Targets in Metastatic Colorectal Cancer: A Review

  2025cites this paper
• Efficacy and safety of third-line or later-line targeted treatment for patients with metastatic colorectal cancer: a meta-analysis

  2023cites this paper
• Progress of research on molecular targeted therapies for colorectal cancer

  2023cites this paper
• Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

  2023cites this paper
• Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review

  2023cites this paper
• Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers

  2021cites this paper
• Preclinical Drug Testing of the CDK 4/6 Inhibitor Palbociclib in Combination With a PI3K or MEK Inhibitor in Colorectal Cancer Cell Lines

  2021cites this paper
• Molecular Targets for the Treatment of Metastatic Colorectal Cancer

  2020cites this paper
• Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).

  2020cites this paper
• A systematic review of salvage therapies in refractory metastatic colorectal cancer

  2020cites this paper
• Administration sequence for multi-agent oncolytic regimens

  2020cites this paper
• Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer

  2019cites this paper
• DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer : New therapeutic opportunities ? 2

  2019cites this paper
• Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors

  2019cites this paper
• A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

  2019cites this paper
• Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer.

  2018cites this paper
• Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review

  2018cites this paper
• RAS testing in metastatic colorectal cancer: advances in Europe

  2018cites this paper
• A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15‐minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin‐ and Irinotecan‐refractory, KRAS Wild‐type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial)

  2018influential citation
• Molecular Cytology Applications in Metastases

  2018cites this paper
• Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis

  2018cites this paper
• Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes.

  2017cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer

  2017cites this paper
• Clinical Genomic Biomarker Assay Development: Technologies and Issues

  2016cites this paper
• Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study)

  2016cites this paper
• A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab

  2016cites this paper
• Mucinous and non-mucinous adenocarcinoma in colorectal cancer patients.

  2016cites this paper
• Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS

  2016cites this paper
• The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer

  2016cites this paper
• An EGFR Pathway-Oriented Pharmacogenetic Study in MetastaticColorectal Cancer Patients Receiving Panitumumab and Irinotecan

  2016cites this paper
• Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan

  2016cites this paper
• New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer

  2016cites this paper
• Anti-Epidermal Growth Factor Receptor (EGFR) Treatment in Patients with Metastatic Colorectal Cancer

  2016cites this paper
• Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study).

  2016cites this paper
• Integrating systemic and surgical approaches to treating metastatic colorectal cancer.

  2015cites this paper
• Panitumumab for the treatment of metastatic colorectal cancer: a review.

  2015cites this paper
• Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer

  2015cites this paper
• Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers.

  2015cites this paper
• Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2

  2015influential citation
• Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer

  2015cites this paper
• [DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].

  2015cites this paper
• Ethics and genomic medicine, how to navigate decisions in surgical oncology

  2015cites this paper
• Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

  2015cites this paper
• Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran

  2015cites this paper
• Pragmatic issues in biomarker evaluation for targeted therapies in cancer

  2015cites this paper
• RAS testing in metastatic colorectal cancer: advances in Europe

  2015cites this paper
• Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites

  2014cites this paper
• Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced

  2014cites this paper
• Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer12

  2014cites this paper
• Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.

  2014cites this paper
• Panitumumab safety for treating colorectal cancer

  2014cites this paper
• A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.

  2014cites this paper
• PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

  2014cites this paper
• Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics

  2014cites this paper
• Past, current and future approaches to querying MAPK pathway activation: status and clinical implications.

  2014cites this paper
• Colorectal cancer defeating? Challenge accepted!

  2014cites this paper
• Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine

  2014cites this paper
• [Major advances in Oncology in 2013: the editorial board of the Bulletin du Cancer point of view].

  2014cites this paper
• Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

  2014cites this paper
• Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.

  2014cites this paper
• structural pharmacology to study complex diseases and personalized medicine.

  2014cites this paper
• Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

  2014cites this paper
• Panitumumab: leading to better overall survival in metastatic colorectal cancer?

  2014cites this paper
• Predictive Biomarkers and Personalized Medicine Hsa-miR-31-3 p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

  2014cites this paper
• KRAS mutations: analytical considerations.

  2014cites this paper
• Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review

  2014influential citation
• Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives

  2014cites this paper
• The Role of Predictive Molecular Biomarkers for the Treatment of Metastatic Colorectal Cancer

  2014cites this paper
• A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer

  2014cites this paper
• Management of locally advanced and metastatic colon cancer in elderly patients.

  2014cites this paper
• Practical Guidance for Implementing Predictive Biomarkers into Early Phase Clinical Studies

  2013cites this paper
• Epidermal growth factor receptor: pathway, therapies, and pipeline.

  2013cites this paper
• Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.

  2013cites this paper
• Investigating the genetics and pharmacogenetics of bowel cancer

  2013cites this paper
• RAS mutations: impact on treatment outcome

  2013cites this paper
• The role of SLIRP and Notch signalling in colorectal cancer

  2013cites this paper
• Development and Validation of a Clinical Trial Patient Stratification Assay That Interrogates 27 Mutation Sites in MAPK Pathway Genes

  2013cites this paper
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

  2013cites this paper
• Surgery: Cetuximab—an option for unresectable CRC liver metastases

  2013cites this paper
• Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

  2013cites this paper
• Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients

  2013cites this paper
• Therapeutic strategy in unresectable metastatic colorectal cancer

  2012cites this paper
• Clinical Validation and Biomarker Translation

  2010cites this paper
• Cancer Management and Research Dovepress

  year unknowncites this paper
• Cancer Management and Research Dovepress

  year unknowncites this paper
• World Journal of Clinical Oncology

  year unknowninfluential citation